Using Artificial Intelligence to support Quantitative Digital Pathology in R&D
2 November 2021
By Mark Laurie

About this Webinar:

This session, ‘Using Artificial Intelligence (AI) to support Quantitative Digital Pathology in R&D’, was live on Wednesday 17th November 2021. You can re-watch the full webinar including the Q&A above.

Presented by OracleBio’s Chief Scientific Officer, Lorcan Sherry, it covered:

  • Using AI Deep Learning to improve image analysis accuracy and turn-around time in a pre-clinical tumor IHC study
  • Integrating clinical pathologist input in development and validation of a Deep Learning Tissue Classifier App
  • Advantages of implementing Deep Learning for tissue segmentation and cell detection in multiplex IF studies
  • and more…

Lorcan Sherry

Chief Scientific Officer

As co-founder and Chief Scientific Officer at OracleBio, Lorcan has helped establish the company as a market leader within its field, supporting the digital pathology programmes of major Pharma and Biotech companies around the globe.

Day to day, Lorcan oversees a team of image analysis scientists and pathologists responsible for the execution of Client image analysis R&D studies, while further driving the adoption of innovative techniques and processes to improve the quality and efficiency of our services.

More from OracleBio:

Find out more about our Multiplex IF Analysis

OracleBio's Quantitative Digital Pathology Services

Stay up to date with OracleBio

Sign up to our mailing list to stay informed about news, webinars, events and more